ICD-10 ‘grace period’ ending soon, but don’t panic
August 1st 2016By now, most of you are relatively fluent in the urology diagnosis codes that affect payment for the services provided in the urology office. Of course, we are now facing the end of the ICD-10 “grace period,” and fears of denials for bad diagnosis codes are once again starting to circulate. This begs the question, what should you do now?
MACRA pay models: What you can expect
June 1st 2016In a series of articles this year, Robert A. Dowling, MD, will examine what you need to know about the law, what the CMS proposed rule for implementation implies for the near and long-term future, and-when it is issued later this year-what the final rule means to your urology practice.
MIPS: A first look at how it will affect your practice
June 1st 2016The Centers for Medicare & Medicaid Services (CMS) has released a proposed rule regarding the implementation of the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015. This article will summarize some of the details of the proposed rule, including an outline of the Merit-Based Incentive Payment System (MIPS), one of the key components of MACRA.
What overpayments rule means for your practice
April 1st 2016Medicare Part B charges and payments constitute a significant fraction of the typical urology practice’s income, and owners of these practices should be aware of the pertinent rules and regulations-and the consequences of failure to comply with them.
Meaningful use's directional shift
February 1st 2016The federal government’s aggressive timeline for full Stage 3 implementation of meaningful use in 2018 seemed to derail on Jan. 11 when Acting CMS Administrator Andy Slavitt declared that the program would come to an end this year. Now that the news has settled, urologists are among those who think meaningful use is very much alive, but evolving, and urologists and other physicians should not change EHR course, just yet.
Uro Pipeline: 1st patients treated in phase III study of investigational BPH Tx
January 1st 2016Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.